|
Canada-861102-Associations कंपनी निर्देशिकाएँ
|
कंपनी समाचार :
- Prostate-Specific Antigen (PSA) Test - NCI - National Cancer Institute
Prostate-specific antigen, or PSA, is a protein produced by normal, as well as malignant, cells of the prostate gland Both prostate cancer and several benign conditions (particularly benign prostatic hyperplasia, or BPH, and prostatitis) can cause PSA levels in the blood to rise The PSA test measures the level of PSA in the blood
- Understanding Prostate Changes and Conditions - National Cancer Institute
When men are in their 20s, the normal prostate is about the size of a walnut By the time a man is 40 the prostate may have grown slightly larger, and by age 60, the prostate is often the size of a lemon Can prostate cancer be detected early? PSA testing is sometimes used to screen for prostate cancer There are both possible benefits and
- Prueba del antígeno prostático específico (PSA)
El antígeno prostático específico o PSA es una proteína que producen tanto las células normales como las células malignas (cancerosas) de la próstata Tanto el cáncer de próstata como varias afecciones benignas (en particular la hiperplasia prostática benigna, o HPB, y la prostatitis) hacen que aumenten las concentraciones del PSA en la sangre
- Prostate Cancer Treatment - NCI - National Cancer Institute
Prostate cancer is a type of cancer that forms in the tissues of the prostate The prostate is a gland in the male reproductive system It lies just below the bladder (the organ that collects and empties urine) and in front of the rectum (the lower part of the intestine) It is about the size of a walnut and surrounds part of the urethra (the tube that empties urine from the bladder)
- PSA Velocity Does Not Improve Prostate Cancer Detection
In that clinical trial, men ages 55 or older with a PSA level below 3 0 ng ml and a normal DRE result at study entry were randomly assigned to receive either the drug finasteride or a placebo The online calculator estimates the likelihood that a biopsy will detect prostate cancer in general and high-grade prostate cancer in particular
- Prostate Cancer Screening Results from PLCO - NCI
Most men with an elevated PSA test turn out not to have cancer; only 25 to 30 percent of men who have a biopsy due to elevated PSA levels actually have prostate cancer False-negative tests: False-negative test results (also called false negatives) occur when the PSA level is in the normal range even though prostate cancer is actually present
- Prostate Cancer Screening (PDQ®) - NCI - National Cancer Institute
It has been reported that 25% of men presenting with metastatic disease had a normal prostate examination Another case-control study examining screening with both DRE and prostate-specific antigen (PSA) found a reduction in prostate cancer mortality that was not statistically significant (odds ratio [OR], 0 7; 95% confidence interval [CI], 0
- Prostate Cancer Screening - NCI - National Cancer Institute
Prostate cancer is a disease in which malignant (cancer) cells form in the tissues of the prostate The prostate is a gland in the male reproductive system It lies just below the bladder (the organ that collects and empties urine) and in front of the rectum (the lower part of the intestine) It is about the size of a walnut and surrounds part of the urethra (the tube that empties urine from the
- Hormone Therapy for Prostate Cancer Fact Sheet - NCI
Androgens promote the growth of both normal and cancerous prostate cells by binding to and activating the androgen receptor, An increase in PSA level may indicate that a man’s cancer has started growing again or become resistant to the hormone therapy that is currently being used Prostate Cancer and Prostatic Diseases 2007; 10(4):340
- Prostate Cancer Screening | Cancer Trends Progress Report
Prostate-specific antigen, or PSA, is a protein produced by normal, as well as malignant, cells of the prostate gland The PSA test measures the level of PSA in a man’s blood For this test, a blood sample is sent to a laboratory for analysis In 2012 the U S Preventive Services Task Force (USPSTF) recommended against prostate cancer screening
|
|